
Giuseppe Lanzarone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9849064/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood, 2020, 136, 171-182.	1.4	65
2	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. Blood Cancer Journal, 2018, 8, 49.	6.2	30
3	The use of erythropoiesisâ€ s timulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. British Journal of Haematology, 2018, 182, 701-704.	2.5	22
4	Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study. Annals of Hematology, 2022, 101, 855-867.	1.8	19
5	Can pegylated interferon improve the outcome of polycythemia vera patients?. Journal of Hematology and Oncology, 2017, 10, 15.	17.0	15
6	Association of Platelet Thromboxane Inhibition by Lowâ€Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia. Clinical Pharmacology and Therapeutics, 2022, 111, 939-949.	4.7	6
7	The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms. Medicina (Lithuania), 2021, 57, 813.	2.0	2